US Stock MarketDetailed Quotes

GNPX Genprex

Watchlist
  • 0.4181
  • -0.0228-5.17%
Trading Feb 18 10:58 ET
3.56MMarket Cap-0.04P/E (TTM)

About Genprex Company

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Company Profile

SymbolGNPX
Company NameGenprex
Listing DateMar 29, 2018
Issue Price5.00
Founded2009
CEOMr. Ryan M. Confer
MarketNASDAQ
Employees26
Fiscal Year Ends12-31
Address3300 Bee Cave Road,Suite 650-227
CityAustin
ProvinceTexas
CountryUnited States of America
Zip Code78746
Phone1-877-774-4679

Company Executives

  • Name
  • Position
  • Salary
  • Ryan M. Confer
  • Director, President, Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Mark S. Berger, M.D.
  • Chief Medical Officer
  • 947.11K
  • Brent Longnecker
  • Independent Director
  • 161.61K
  • William R. Wilson, Jr
  • Independent Director
  • 151.16K
  • Jose Antonio Moreno Toscano
  • Independent Director
  • 161.61K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Major earnings are approaching! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1 Show More